| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Agranulocytosis | D000380 | 7 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Amnesia | D000647 | 12 associated lipids |
| Anaphylaxis | D000707 | 35 associated lipids |
| Anemia, Sickle Cell | D000755 | 34 associated lipids |
| Angina Pectoris | D000787 | 27 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
| Hypoxia | D000860 | 23 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Eche N et al. | Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). | 1986 | Thromb. Res. | pmid:3726808 |
| Kakishita E et al. | Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. | 1990 | Thromb. Res. | pmid:2082481 |
| Chang GT et al. | Purification and characterization of a new anticoagulant protein, PP27, from placenta. | 2005 | Thromb. Res. | pmid:16122555 |
| Simon MF et al. | Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. | 1987 | Thromb. Res. | pmid:3576518 |
| Bochkov VN et al. | LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. | 1991 | Thromb. Res. | pmid:2063348 |
| Alam I and Silver MJ | Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. | 1987 | Thromb. Res. | pmid:3576519 |
| Filep JG et al. | C-reactive protein inhibits binding of platelet-activating factor to human platelets. | 1991 | Thromb. Res. | pmid:2063349 |
| Slattery CW and Beaumont DO | Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. | 1989 | Thromb. Res. | pmid:2554526 |
| Liu X et al. | Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. | 2014 | Thromb. Res. | pmid:25223809 |
| Namm DH and High JA | Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. | 1980 | Thromb. Res. | pmid:7209881 |
| Bretschneider E et al. | ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. | 1994 | Thromb. Res. | pmid:7992234 |
| Jones KP et al. | Salivary PAF in acute myocardial infarction and angina: changes during hospital treatment and relationship to cardiac enzymes. | 1994 | Thromb. Res. | pmid:7992251 |
| Juhan-Vague I et al. | Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. | 1985 | Thromb. Res. | pmid:3923649 |
| Westwick J et al. | Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. | 1986 | Thromb. Res. | pmid:3715810 |
| Kloprogge E et al. | Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. | 1983 | Thromb. Res. | pmid:6222507 |
| Ishii H et al. | Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. | 1990 | Thromb. Res. | pmid:2382255 |
| Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. | 1987 | Thromb. Res. | pmid:3647677 |
| Hofmann B et al. | Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. | 1988 | Thromb. Res. | pmid:3381200 |
| Davis RB and Johnson MF | Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. | 1986 | Thromb. Res. | pmid:3544327 |
| Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
| Glusa E et al. | Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. | 1989 | Thromb. Res. | pmid:2528843 |
| Stahl GL et al. | Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. | 1989 | Thromb. Res. | pmid:2718150 |
| Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
| Petty AC and Scrutton MC | Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? | 1989 | Thromb. Res. | pmid:2749609 |
| Lalau Keraly C et al. | Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. | 1984 | Thromb. Res. | pmid:6740569 |
| Beaumont DO et al. | Measuring platelet function with platelet shape change, an early event in aggregation. | 1989 | Thromb. Res. | pmid:2646752 |
| Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
| Suttorp N et al. | Stimulation of PAF-synthesis in pulmonary artery endothelial cells by Staphylococcus aureus alpha-toxin. | 1992 | Thromb. Res. | pmid:1440526 |
| Moon DG et al. | Platelet activating factor and sheep platelets: a sensitive new bioassay. | 1990 | Thromb. Res. | pmid:2326773 |
| Violi F et al. | Human platelet aggregation by PAF and thromboxane production. | 1987 | Thromb. Res. | pmid:3424290 |
| Benveniste J et al. | Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. | 1982 | Thromb. Res. | pmid:6803388 |
| Seth P et al. | Effect of platelet activating factor antagonists in different models of thrombosis. | 1994 | Thromb. Res. | pmid:7900097 |
| Bernat A and Herbert JM | Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. | 1994 | Thromb. Res. | pmid:8073411 |
| Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
| Chlopicki S et al. | Obligatory role of lipid mediators in platelet-neutrophil adhesion. | 2003 | Thromb. Res. | pmid:14592550 |
| Valone FH and Johnson B | Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. | 1985 | Thromb. Res. | pmid:4082115 |
| Kawamura M et al. | Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. | 1993 | Thromb. Res. | pmid:8332959 |
| Kohayakawa M and Inoue K | Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. | 1986 | Thromb. Res. | pmid:3083530 |
| Ostermann G et al. | The role of lipoproteins in the degradation of platelet-activating factor. | 1986 | Thromb. Res. | pmid:3798402 |
| Stormorken H et al. | A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). | 1983 | Thromb. Res. | pmid:6857589 |
| Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
| Leoncini G et al. | Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. | 1997 | Thromb. Res. | pmid:9175236 |
| Despotis GJ et al. | Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. | 1997 | Thromb. Res. | pmid:9175242 |
| Hayashi M et al. | Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. | 1987 | Thromb. Res. | pmid:3433255 |
| Ostermann G et al. | The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. | 1988 | Thromb. Res. | pmid:3232123 |
| Avdonin PV et al. | Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. | 1988 | Thromb. Res. | pmid:3232128 |
| Lecompte T et al. | Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. | 1990 | Thromb. Res. | pmid:2117306 |
| Mabilat-Pragnon C et al. | Urokinase localization and activity in isolated eosinophils. | 1997 | Thromb. Res. | pmid:9526961 |
| Kinlough-Rathbone RL et al. | Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. | 1999 | Thromb. Res. | pmid:10527409 |
| Patterson WR et al. | Aggregation of killer whale platelets. | 1993 | Thromb. Res. | pmid:8327987 |